Aloglip Tablet

About Aloglip 6.25 mg Tablet

This page describes Aloglip 6.25 mg Tablet, a tablet with the generic name Alogliptin Benzoate and a strength of 6.25 mg. The listed drug class is Dipeptidyl Peptidase-4 (DPP-4) inhibitor. It is manufactured by Navana Pharmaceuticals Ltd. The information on this page starts its indications with: “Alogliptin is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type-2 diabetes mellitus”. You can compare Aloglip with the other brands of Alogliptin Benzoate further down this page, sorted from the lowest price. Aloglip has a listed unit price of Tk 8.00. A pack price of Tk 240.00 (3 x 10) is also listed. This text is for general reference; the dose and duration should always come from a doctor, and a pharmacist can help with questions about brands.

There are 7 brands of Alogliptin Benzoate listed in Bangladesh. By unit price, Aloglip is among the cheapest of them.

Indications

Alogliptin is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type-2 diabetes mellitus.

Pharmacology

Alogliptin is a DPP-4 inhibitor that slows the inactivation of the incretin hormones, thereby increasing their bloodstream concentrations and reducing fasting and postprandial glucose concentrations in a glucose-dependent manner in patients with type 2 diabetes mellitus. Increased concentrations of the incretin hormones such as glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) are released into the bloodstream from the small intestine in response to meals. These hormones cause insulin release from the pancreatic beta cells in a glucose-dependent manner but are inactivated by the DPP-4 enzyme within minutes. GLP-1 also lowers glucagon secretion from pancreatic alpha cells, reducing hepatic glucose production. In patients with type 2 diabetes, concentrations of GLP-1 are reduced but the insulin response to GLP-1 is preserved.

Dosage & Administration

The recommended dose in patients with normal renal function or mild renal impairment is 25 mg once daily or as directed by the physicians.

Interaction

Alogliptin is primarily renally excreted. Cytochrome (CYP) P450-related metabolism is negligible. No significant drug-drug interactions are observed with the CYP-substrates or inhibitors tested or with renally excreted drugs.

Contraindications

History of a serious hypersensitivity reaction to Alogliptin-containing products, such as anaphylaxis, angioedema or severe cutaneous adverse reactions.

Side Effects

Common side effects are nasopharyngitis, headache and upper respiratory tract infection.

Pregnancy & Lactation

Pregnancy Category B. No adequate or well-controlled studies in pregnant women have been conducted with Alogliptin. Alogliptin tablets should be used during pregnancy only if clearly needed. It is not known whether Alogliptintin is excreted in human milk. caution should be exercised when Alogliptin is administered to a nursing woman.

Precautions & Warnings

Acute pancreatitis: If pancreatitis is suspected, promptly Alogliptin should be discontinued.

Hypersensitivity: There have been postmarketing reports of serious hypersensitivity reactions in patients treated with Alogliptin such as anaphylaxis, angioedema and severe cutaneous adverse reactions. In such cases, promptly Alogliptin should be discontinued.

Hepatic effects: Postmarketing reports of hepatic failure, sometimes fatal. Causality can not be excluded. If liver injury is detected, promptly interrupt Alogliptin and assess patient for probable cause, then treat cause if possible, to resolution or stabilization. Do not restart Alogliptin if liver injury is confirmed and no alternative etiology can be found.

Hypoglycemia: When an insulin secretagogue (e.g. sulfonylurea) or insulin is used in combination with Alogliptin, a lower dose of the insulin secretagogue or insulin may be required to minimize the risk of hypoglycaemia.

Macrovascular outcomes: There have been no clinical studies establishing conclusive evidence of macrovascular risk reduction with Alogliptin or any other antidiabetic drug.

Overdose Effects

The highest doses of Alogliptin administered in clinical trials were single doses of 800 mg to healthy subjects and doses of 400 mg once daily for 14 days to patients with type 2 diabetes (equivalent to 32 times and 16 times the maximum recommended clinical dose of 25 mg, respectively). No serious adverse events were observed at these doses. In the event of an overdose, it is reasonable to institute the necessary clinical monitoring and supportive therapy as dictated by the patient's clinical status. Per clinical judgment, it may be reasonable to initiate removal of unabsorbed material from the gastrointestinal tract. Alogliptin is minimally dialyzable; over a 3-hour hemodialysis session, approximately 7% of the drug was removed. Therefore, hemodialysis is unlikely to be beneficial in an overdose situation. It is not known if Alogliptin is dialyzable by peritoneal dialysis.

Storage Conditions

Keep below 30°C temperature, away from light & moisture. Keep out of the reach of children.

Alternative brands of Alogliptin Benzoate

Other brands with the same generic name, cheapest first.

Medicine information is for reference only and is not medical advice. Always follow your doctor's prescription and check with a pharmacist.